摘要
聚腺苷二磷酸核糖聚合酶(PARP)是关键的DNA单链损伤修复酶,近年来研究发现,PARP抑制剂不仅可增加肿瘤对放化疗的敏感程度,还能被单独用于同源重组修复缺陷的肿瘤的治疗,具有良好的应用前景。对临床在研的PARP抑制剂的抗肿瘤作用研究近况进行介绍,旨在为相关药物的研发提供参考。
Poly （ADP-ribose） polymerase （PARP） is a critical enzyme in DNA single-strand damage repair. Recently, more and more researches have shown that PARP inhibitors can improve the sensitivity of tumors to radiotherapy and chemotherapy, and selectively kill homologous recombination repair-defective tumors as monotherapy. They have good prospect in clinical application. The research status of PARP inhibitors in anti-tumor therapy was reviewed in this paper, so as to provide reference for the development of related new drugs.
出处
《药学进展》
CAS
2013年第5期215-221,共7页
Progress in Pharmaceutical Sciences
基金
科技基础设施建设计划--江苏省创新平台提升项目(No.BM2012012)
国家"十二五"重大新药创制资助项目(No.2012ZX09103-101-031)
